LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

NCT07362186 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

Interventions

DRUG: LM-108 in combination with Toripalimab
DRUG: Paclitaxel injection intravenous infusion

Sponsor

LaNova Medicines Limited